Journal of Neuroimmune Pharmacology

, Volume 1, Issue 3, pp 280–295 | Cite as

Drugs of Abuse, Immune Modulation, and AIDS

Invited Review

Abstract

Illicit drugs such as amphetamines, cocaine, marijuana, and opiates alter immune function and decrease host resistance to microbes in vitro and in experimental animal models. Effects on the immune system may be mediated indirectly as a result of drug interactions in the central nervous system (CNS) or directly through activation of cognate receptors on various immune cell types. For marijuana and opioids, seven-transmembranal G protein-coupled receptors have been identified in the CNS and in the immune system that may play a functionally relevant role in immune modulation. There is accumulating evidence that sigma1 receptors play a comparable role in cocaine-mediated alteration of immune responses. A mode by which these exogenously introduced substances affects immunity and host resistance may be by perturbing the balance of Th1 proinflammatory versus Th2 anti-inflammatory cytokines and lipid bioeffectors. However, while illicit drugs have been documented to alter immune functions in vitro and in animal models, there is a paucity of controlled longitudinal epidemiological studies that definitively correlate immunosuppressive effects with increased incidence of infections or immune disorders in humans, including infection with the human immunodeficiency virus (HIV) or disease progression to AIDS.

Key words

AIDS amphetamines cannabinoids cocaine cocaethylene drugs of abuse HIV illicit drugs immunity infections ketamine marijuana methadone methamphetamine morphine opioids 

Notes

Acknowledgements

This study was supported in part by DA05832 and DA15608 from the National Institute on Drug Abuse (NIDA).

References

  1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139:258–266PubMedGoogle Scholar
  2. Adler MW, Geller EB, Rogers TJ, Henderson EE, Eisenstein TK (1993) Opioids, receptors, and immunity. Adv Exp Med Biol 335:13–20PubMedGoogle Scholar
  3. Alonzo NC, Bayer BM (2002) Opioids, immunology, and host defenses of intravenous drug abusers. Infect Dis Clin North Am 16:553–569PubMedGoogle Scholar
  4. Anthony JC, Vlahov D, Nelson KE, Cohn S, Astemborski J, Solomon L (1991) New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol 134:1175–1189PubMedGoogle Scholar
  5. Arata S, Klein TW, Newton C, Friedman H (1991) Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sci 49:473–479PubMedGoogle Scholar
  6. Arata S, Newton C, Klein T, Friedman H (1992) Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proc Soc Exp Biol Med 199:65–67PubMedGoogle Scholar
  7. Avila AH, Morgan CA, Bayer BM (2003) Stress-induced suppression of the immune system after withdrawal from chronic cocaine. J Pharmacol Exp Ther 305:290–297PubMedGoogle Scholar
  8. Beagles K, Wellstein A, Bayer B (2004) Systemic morphine administration suppresses genes involved in antigen presentation. Mol Pharmacol 65:437–442PubMedGoogle Scholar
  9. Blahoutova V, Zajicova A, Wilczek H, Holan V (2003) Opioids and their immunomodulatory properties. Cas Lek Cesk 142:244–247PubMedGoogle Scholar
  10. Bradley SG, Munson AE, Dewey WL, Harris LS (1977) Enhanced susceptibility of mice to combinations of delta 9-tetrahydrocannabinol and live or killed gram-negative bacteria. Infect Immun 17:325–329PubMedGoogle Scholar
  11. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI (2002) Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42:82S–89SPubMedGoogle Scholar
  12. Brown JM, Hanson GR, Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221–2223PubMedGoogle Scholar
  13. Bruneau J, Lamothe F, Soto J, Lachance N, Vincelette J, Vassal A, Franco EL (2001) Sex-specific determinants of HIV infection among injection drug users in Montreal. CMAJ 164:767–773PubMedGoogle Scholar
  14. Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA (1993) Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette–Guerin-activated macrophages. Int J Immunopharmacol 15:371–382PubMedCrossRefGoogle Scholar
  15. Cabral GA (2005) Lipids as bioeffectors in the immune system. Life Sci 77:1699–1710PubMedGoogle Scholar
  16. Cabral GA, Dove Pettit DA (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83:116–123PubMedGoogle Scholar
  17. Cabral GA, Marciano-Cabral F (2004) Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 147:127–130PubMedGoogle Scholar
  18. Cabral GA, Staab A (2005) Effects on the immune system. Hand Exp Pharmacol 168:385–423Google Scholar
  19. Cabral GA, Vasquez R (1991) Effects of marijuana on macrophage function. Adv Exp Med Biol 288:93–105PubMedGoogle Scholar
  20. Cabral GA, Vasquez R (1992) delta 9-Tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity. Proc Soc Exp Biol Med 199:255–263PubMedGoogle Scholar
  21. Cabral GA, Lockmuller JC, Mishkin EM (1986a) Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc Soc Exp Biol Med 181:305–311PubMedGoogle Scholar
  22. Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, Munson AE (1986b) Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infectio in the guinea pig. Proc Soc Exp Biol Med 182:181–186PubMedGoogle Scholar
  23. Caiaffa WT, Vlahov D, Graham NM, Astemborski J, Solomon L, Nelson KE, Munoz A (1994) Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 150:1493–1498PubMedGoogle Scholar
  24. Carpenter CW, Carza HH Jr, Cebhardt BM, Carr DJ (1994) Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain Behav Immun 8:185–203PubMedGoogle Scholar
  25. Carr DJ, France CP (1993) Immune alterations in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 267:9–15PubMedGoogle Scholar
  26. Carr DJ, Serou M (1995) Exogenous and endogenous opioids as biological response modifiers. Immunopharmacology 31:59–71PubMedGoogle Scholar
  27. Chang SL, Wu GD, Patel NA, Vidal EL, Fiala M (1998) The effects of interaction between morphine and interleukin-I on the immune response. Adv Exp Med Biol 437:67–72PubMedGoogle Scholar
  28. Cheido MA, Idova GV (1994) Participation of opiate delta-receptors in immunomodulation. Neurosci Behav Physiol 24:479–482PubMedGoogle Scholar
  29. Chaisson MA, Stoneburner RL, Hildebrandt DS, Ewing WE, Telzak EE, Jaffe HW (1991) Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS 5:1121–1126Google Scholar
  30. Coates RA, Farewell VT, Raboud J, Read SE, MacFadden DK, Calzavara LM, Johnson JK, Shepherd FA, Fanning MM (1990) Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol 132:717–722PubMedGoogle Scholar
  31. Cohen S (1976) The 94-day cannabis study. Ann N Y Acad Sci 282:211–220PubMedGoogle Scholar
  32. Colfax C, Shoptaw S (2005) The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2:194–199PubMedGoogle Scholar
  33. Cook RL, May S, Harrison LH, Moreira RI, Ness RB, Batista S, Bastos MS, Schechter M (2004) High prevalence of sexually transmitted diseases in young women seeking HIV testing in Rio de Janeiro, Brazil. Sex Transm Dis 31:67–72PubMedGoogle Scholar
  34. Crosby R, Diclemente RJ, Wingood GM, Harrington K, Davies SL, Hook EW III, Oh MK (2002) Predictors of infection with Trichomonas vaginalis: a prospective study of low income African-American adolescent females. Sex Transm Infect 78:360–364PubMedGoogle Scholar
  35. Daaka Y, Klein TW, Friedman H (1995) Expression of cannabinoid receptor mRNA in murine and human leukocytes. Adv Exp Med Biol 373:91–96PubMedGoogle Scholar
  36. Delafuente JC, DeVane CL (1991) Immunologic effects of cocaine and related alkaloids. Immunopharmacol Immunotoxicol 13:11–23PubMedGoogle Scholar
  37. Di Franco MJ, Marlink R, Hunter DJ, Tosteson T, Mayer K, Essex M (1993) Association of immune activation with intravenous heroin use and methadone treatment in HIV-1 seropositive and seronegative subjects. J Acquir Immune Syndr 6:1297–1300Google Scholar
  38. Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS (1996) The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. Ann Epidemiol 6:283–289PubMedGoogle Scholar
  39. Donahoe RM, Falek A (1988) Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS. Adv Biochem Psychopharmacol 44:145–158PubMedGoogle Scholar
  40. Donahoe RM, Nicholson JK, Madden JJ, Donahoe F, Shafer DA, Gordon D, Bokos P, Falek A (1986) Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin Immunol Immunopathol 41:254–264PubMedGoogle Scholar
  41. Friedman H (1996) Drugs of abuse as possible co-factors in AIDS progression: summary of panel discussion. Adv Exp Med Biol 402:225–228PubMedGoogle Scholar
  42. Friedman H, Newton C, Klein TW (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 16:209–219PubMedGoogle Scholar
  43. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61PubMedGoogle Scholar
  44. Garza HH Jr, Prakash O, Carr DJ (1994) Immunologic characterization of TAT72-transgenic mice: effects of morphine on cell-mediated immunity. Int J Immunopharmacol 16:1061–1070PubMedGoogle Scholar
  45. Goedert JJ (1984) Recreational drugs: relationship to AIDS. Ann N Y Acad Sci 437:192–199PubMedGoogle Scholar
  46. Greenfield L, Bigelow GE, Brooner RK (1992) HIV risk behavior in drug users: increased blood “booting” during cocaine injection. AIDS Educ Prev 4:95–107PubMedGoogle Scholar
  47. Gross G, Roussaki A, Ikenberg H, Drees N (1991) Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption. Dermatologica 183:203–207PubMedCrossRefGoogle Scholar
  48. Harkess J, Gildon B, Istre GR (1989) Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984–87. Am J Public Health 79:463–466PubMedGoogle Scholar
  49. Havas HF, Dellaria M, Schiffman G, Geller EB, Adler MW (1987) Effect of cocaine on the immune response and host resistance in BALB/c mice. Int Arch Allergy Appl Immunol 83:377–383PubMedGoogle Scholar
  50. Haverkos HW, Curran JW (1982) The current outbreak of Kaposi's sarcoma and opportunistic infections. CA Cancer J Clin 32:330–339PubMedGoogle Scholar
  51. Hendrickson M, Shelby J, Sullivan JJ, Saffle JR (1989) Naloxone inhibits the in vivo immunosuppressive effects of morphine and thermal injury in mice. J Burn Care Rehabil 10:494–498PubMedGoogle Scholar
  52. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42:63–71PubMedGoogle Scholar
  53. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1–20PubMedGoogle Scholar
  54. Horsburgh CR Jr, Anderson JR, Boyko EJ (1989) Increased incidence of infections in intravenous drug users. Infect Control Hosp Epidemiol 10:211–215PubMedGoogle Scholar
  55. House RV, Thomas PT, Bhargava HN (1994) Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol Immunotoxicol 16:1–21PubMedGoogle Scholar
  56. House RV, Thomas PT, Bhargava HN (1995) Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). Toxicology 96:59–69PubMedGoogle Scholar
  57. House RV, Thomas PT, Bhargava HN (1996) A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides. Peptides 17:75–81PubMedGoogle Scholar
  58. Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307–313PubMedGoogle Scholar
  59. Hughes SC, Dailey PA, Landers D, Dattel BJ, Crombleholme WR, Johnson JL (1995) Parturients infected with human immunodeficiency virus and regional anesthesia. Clinical and immunologic response. Anesthesiology 82:32–37PubMedGoogle Scholar
  60. Itzhak Y (1989) Multiple affinity binding sites of the sigma receptor: effect of GTP-binding protein-modifying agents. Mol Pharmacol 36:512–517PubMedGoogle Scholar
  61. Itzhak Y, Stein I (1990) Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci 47:1073–1081PubMedGoogle Scholar
  62. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, Heaton RK, Ellis RJ, Grant I (2005) Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 162:1461–1472PubMedGoogle Scholar
  63. Joe GW, Knezek L, Watson D, Simpson DD (1991) Depression and decision-making among intravenous drug users. Psychol Rep 68:339–347PubMedGoogle Scholar
  64. Jones S, Kauer JA (1999) Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area. J Neurosci 19:9780–9787PubMedGoogle Scholar
  65. Juel-Jensen BE (1972) Cannabis and recurrent herpes simplex. Br Med J 4:296PubMedGoogle Scholar
  66. Kagen SL, Kurup VP, Sohnle PG, Fink JN (1983) Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 71:389–393PubMedGoogle Scholar
  67. Kall KI, Olin RG (1990) HIV status and changes in risk behaviour among intravenous drug users in Stockholm 1987–1988. AIDS 4:153–157PubMedCrossRefGoogle Scholar
  68. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO (1989) No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA 261:3424–3429PubMedGoogle Scholar
  69. Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen presenting cells. J Neuroimmune Pharmacol 1:1–15Google Scholar
  70. Klein TW, Newton C, Widen R, Friedman H (1993) Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267:635–640PubMedGoogle Scholar
  71. Klein TW, Newton CA, Nakachi N, Friedman H (2000) Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 164:6461–6466PubMedGoogle Scholar
  72. Kowalski J (1998) Immunomodulatory action of class mu-, delta- and kappa-opioid receptor agonists in mice. Neuropeptides 32:301–306PubMedGoogle Scholar
  73. Kuhar MJ (1992) Molecular pharmacology of cocaine: A dopamine hypothesis and its implications. Ciba Found Symp 166:81–89PubMedGoogle Scholar
  74. Kump DF, Matulka RA, Burton GF, Jordan SD, Holsapple MP (1996) Alternations in splenocyte and thymocyte subpopulations in B6C3FI mice exposed to cocaine plus diazinon. J Pharmacol Exp Ther 277:1477–1485PubMedGoogle Scholar
  75. Li Y, Wang X, Tian 5, Guo CJ, Douglas SD, Ho WZ (2002) Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 185:118–122PubMedGoogle Scholar
  76. Li PF, Hao YS, Huang DA, Liu XH, Liu SL, Li C (2004) Morphine-promoted survival of CEMx174 cells in early stages of SIV infection In Vitro: involvement of the multiple molecular mechanisms. Toxicol in vitro 18:449–456PubMedGoogle Scholar
  77. Liau A, Diclemente RJ, Wingood GM, Crosby RA, Williams KM, Harrington K, Davies SL, Hook EW III, Oh MK (2002) Associations between biologically confirmed marijuana use and laboratory-confirmed sexually transmitted diseases among African American adolescent females. Sex Transm Dis 29:387–390PubMedGoogle Scholar
  78. Lindsay MK, Johnson N, Peterson HB, Willis S, Williams H, Klein L (1992) Human immunodeficiency virus infection among inner-city adolescent parturients undergoing routine voluntary screening, July 1987 to March 1991. Am J Obstet Gynecol 167:1096–1099PubMedGoogle Scholar
  79. Liu Y, Montes 5, Zhang D, Sepulveda RT, Yu Q, Zhang J, Larson DF, Watson RR (2002) Cocaethylene and heart disease during murine AIDS. Int Immunopharmacol 2:139–150PubMedGoogle Scholar
  80. Lopez MC, Watson RR (1994) Effect of cocaine and murine AIDS on lamina propria T and B cells in normal mice. Life Sci 54:L147–L151Google Scholar
  81. Lozada F, Silverman S Jr, Migliorati CA, Conant MA, Volberding PA (1983) Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol 56:491–494PubMedGoogle Scholar
  82. Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma–glioma cells. Proc Natl Acad Sci USA 89:3825–3829PubMedGoogle Scholar
  83. Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP, Nair MP (2002) Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol 169:3589–3599PubMedGoogle Scholar
  84. Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Fernandez SF, Schwartz SA, Nair MP (2005) Morphine exacerbates HIV-1 viral protein gpl20 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res 3:277–288PubMedGoogle Scholar
  85. Mansell PW (1984) Acquired immune deficiency syndrome, leading to opportunistic infections. Kaposi's sarcoma, and other malignancies. Crit Rev Clin Lab Sci 20:191–204PubMedCrossRefGoogle Scholar
  86. Marciano-Cabral F (1988) Biology of Naegleria spp. Microbiol Rev 52:114–133PubMedGoogle Scholar
  87. Marciano-Cabral F, Ferguson T, Bradley SG, Cabral G (2001) Delta-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, exacerbates brain infection by Acanthamoeba. J Eukaryot Microbiol Suppl:4S–5SGoogle Scholar
  88. Martucci C, Panerai AE, Sacerdote P (2004) Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110:385–392PubMedGoogle Scholar
  89. Masten SA, Millard WJ, Karlix JL, Shiverick KT (1996) Evaluation of immune parameters and lymphocyte production of prolactin-immunoreactive proteins after chronic administration of cocaine to pregnant rats. J Pharmacol Exp Ther 277:1090–1096PubMedGoogle Scholar
  90. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned CDNA. Nature 346:561–564PubMedGoogle Scholar
  91. Maurice T, Martin-Fardin R, Romieu P, Matsumoto RR (2002) Sigma(1)(sigma(1)) receptor anagonists represennt a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 26: 499–527PubMedGoogle Scholar
  92. McBride WT, Armstrong MA, McBride SJ (1996) Immunomodulation: an important concept in modern anaesthesia. Anaesthesia 51:465–473PubMedGoogle Scholar
  93. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ (2001) Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 62:111–123PubMedGoogle Scholar
  94. McLachlan C, Crofts N, Wodak A, Crowe S (1993) The effects of methadone on immune function among injecting drug users: a review. Addiction 88:257–263PubMedGoogle Scholar
  95. McCoy CB, Metsch LR, Collado-Mesa F, Arheart KL, Messiah SE, Katz D, Shapshak P (2004) The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida. Mem Inst Oswaldo Cruz 99:789–793PubMedGoogle Scholar
  96. Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR (1994) HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 36:109–113PubMedGoogle Scholar
  97. Medveczky MM, Sherwood TA, Klein TW, Friedman H, Medveczky PG (2004) Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med 2:34PubMedGoogle Scholar
  98. Miller JM Jr, Goodridge C (2000) Antenatal marijuana use is unrelated to sexually transmitted infections during pregnancy. Infect Dis Obstet Gynecol 8:155–157PubMedGoogle Scholar
  99. Mishkin EM, Cabral GA (1985) Delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66:2539–2549PubMedCrossRefGoogle Scholar
  100. Miyagi T, Chuang LF, Lam KM, Kung H, Wang JM, Osburn BI, Chuang RY (2000) Opioids suppress chemokine-mediated migration of monkey neutrophils and monocytes—an instant response. Immunopharmacology 47:53–62PubMedGoogle Scholar
  101. Monnet FP, Blier P, Debonnel G, de Montigny C (1992) Modulation by sigma ligands of N-methyl-d-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn-Schmieddeberg's Arch Pharmacol 346:32–39Google Scholar
  102. Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun 23:670–674PubMedGoogle Scholar
  103. Morin SF, Steward WT, Charlebois ED, Remien RH, Pinkerton SD, Johnson MO, Rotheram-Borus MJ, Lightfoot M, Goldstein RB, Kittel L, Samimy-Muzaffar F, Weinhardt L, Kelly JA, Chesney MA (2005) Predicting HIV transmission risk among HIV-infected men who have sex with men: findings from the healthy living project. J Acquir Immune Defic Syndr 40:226–235PubMedGoogle Scholar
  104. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65PubMedGoogle Scholar
  105. Nemoto T, Brown LS Jr, Foster K, Chu A (1990) Behavioral risk factors of human immunodeficiency virus infection among intravenous drug users and implications for preventive interventions. AIDS Educ Prev 2:116–126PubMedGoogle Scholar
  106. Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, Hersh EM (1985) Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Prev Med 14:81–91PubMedGoogle Scholar
  107. Newton CA, Klein TW, Friedman H (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 62:4015–4020PubMedGoogle Scholar
  108. Noe SN, Nyland SB, Ugen K, Friedman H, Klein TW (1998) Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol 437:223–229PubMedGoogle Scholar
  109. Nunez C, Urzua J (1999) Opioids and the immune system. Rev Med Chile 127:341–348PubMedGoogle Scholar
  110. Nyland SB, Specter S, Im-Sin J, Ugen KE (1998) Opiate effects on in vitro human retroviral infection. Adv Exp Med Biol 437:91–100PubMedGoogle Scholar
  111. Pacifici R, Fiaschi Al, Micheli L, Centini F, Giorgi C, Zuccaro P, Pichini S, Di CS, Bacosi A, Cerretani D (2003) Immunosuppression and oxidative stress induced by acute and chronic exposure to cocaine in rat. Int Immunopharmacol 3:581–592PubMedGoogle Scholar
  112. Palm S, Lehzen 5, Mignat C, Steinmann J, Leimenstoll C, Maier C (1998) Does prolonged oral treatment with sustained-release morphine tablets influence immune function? Anesth Analg 86:166–172PubMedGoogle Scholar
  113. Paradise LJ, Friedman H (1993) Syphilis and drugs of abuse. Adv Exp Med Biol 335:81–87PubMedGoogle Scholar
  114. Parsons LH, Ker TM, Weiss F (1998) Simple microbore high-performance liquid chromatographic method for the determination of dopamine and cocaine from a single in vivo brain microdialysis sample. J Chromatogr B Biomed Sci Appl 709:35–45PubMedGoogle Scholar
  115. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B (2005) HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis 24:115–132PubMedGoogle Scholar
  116. Pellegrino T, Bayer BM (1998) In Vivo effects of cocaine on immune cell function. J Neuroimmunol 83:139–147PubMedGoogle Scholar
  117. Persaud NE, Klaskala W, Tewari T, Shultz J, Baum M (1999) Drug use and syphilis. Co-factors for HIV transmission among commercial sex workers in Guyana. West Indian Med J 48:52–56PubMedGoogle Scholar
  118. Pertwee R (2005) Cannabinoids. Berlin: Spinger-VerlagGoogle Scholar
  119. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF (1987) Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 80:824–831PubMedGoogle Scholar
  120. Peterson PK, Gekker C, Hu S, Sheng WS, Molitor TW, Chao CC (1995) Morphine stimulates phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a C protein-coupled opiate receptor. Adv Neuroimmunol 5:299–309PubMedGoogle Scholar
  121. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR (2004) Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 147:123–126PubMedGoogle Scholar
  122. Pruett SB, Han YC, Fuchs BA (1992) Morphine suppresses primary humoral immune responses by a predominantly indirect mechanism. J Pharmacol Exp Ther 262:923–928PubMedGoogle Scholar
  123. Phillips TR, Billaud JN, Henriksen SJ (2000) Methamphetamine and HIV-1: potential interactions and the use of the FIV/cat model. J Psychopharmacol 14:244–250PubMedCrossRefGoogle Scholar
  124. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223PubMedGoogle Scholar
  125. Rofael HZ, Turkall RM, bdel-Rahman MS (2003) Effect of ketamine on cocaine-induced immunotoxicity in rats. Int J Toxicol 22:343–358PubMedGoogle Scholar
  126. Romieu P, Phan VL, Martin-Fardon R, Maurice T (2002) Involvement of the sigma1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26:444–455PubMedGoogle Scholar
  127. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC (2005) Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 77:1711–1722PubMedGoogle Scholar
  128. Rouveix B (1992) Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie 47:503–512PubMedGoogle Scholar
  129. Roy S, Loh HH (1996) Effects of opioids on the immune system. Neurochem Res 21:1375–1386PubMedGoogle Scholar
  130. Roy S, Wang JH, Balasubramanian S, Sumandeep, Charboneau R, Barke R, Loh HH (2001) Role of hypothalamic–pituitary axis in morphine-induced alteration in thymic cell distribution using mu-opioid receptor knockout mice. J Neuroimmunol 116:147–155PubMedGoogle Scholar
  131. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno C, Ammatuna M, Panerai AE (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90:1411–1414PubMedGoogle Scholar
  132. Shen ML, Luo YD, Hagen K, Wu YB, Ou D (1994a) Immunomodulating activities of cocaine—evaluation of lymphocyte transformation related to other immune functions. Int J Immunopharmacol 16:311–319PubMedGoogle Scholar
  133. Shen HM, Kennedy JL, Ou DW (1994b) Inhibition of cytokine release by cocaine. Int J Immunopharmacol 16:295–300PubMedGoogle Scholar
  134. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD (1997) Marijuana use and mortality. Am J Public Health 87:585–590PubMedGoogle Scholar
  135. Siegel L (1986) AIDS: relationship to alcohol and other drugs. J Subst Abuse Treat 3:271–274PubMedGoogle Scholar
  136. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996) Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35]GTPγS autoradiography in rat brain. J Neurosci 16:8057–8066PubMedGoogle Scholar
  137. Simbayi LC, Kalichman SC, Jooste S, Cherry C, Mfecane S, Cain D (2005) Risk factors for HIV–AIDS among youth in Cape Town, South Africa. AIDS Behav 9:53–61PubMedGoogle Scholar
  138. Specter S, Lancz G, Westrich G, Friedman H (1991) Delta-9-tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection. Int J Immunopharmacol 13:411–417PubMedGoogle Scholar
  139. Spittal PM, Bruneau J, Craib KJ, Miller C, Lamothe F, Weber AE, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT (2003) Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. AIDS Care 15:187–195PubMedGoogle Scholar
  140. Stanulis ED, Jordan SD, Rosecrans JA, Holsapple MP (1997) Disruption of Th1/Th2 cytokine balance by cocaine is mediated by corticosterone. Immunopharmacology 37:25–33PubMedGoogle Scholar
  141. Starec M, Rouveix B, Sinet M, Chau F, Desforges B, Pocidalo JJ, Lechat P (1991) Immune status and survival of opiate- and cocaine-treated mice infected with Friend virus. J Pharmacol Exp Ther 259:745–750PubMedGoogle Scholar
  142. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827–831PubMedGoogle Scholar
  143. Szabo G (1997) Alcohol's contribution to compromised immunity. Alcohol Health Res World 21:30–41PubMedGoogle Scholar
  144. Su TP (1991) Sigma receptors. Putative links between nervous, endocrine and immune systems. Eur J Biochem 200:633–642PubMedGoogle Scholar
  145. Suzuki S, Chuang AJ, Chuang LF, Doi RH, Chuang RY (2002) Morphine promotes simian acquired immunodeficiency syndrome virus replication in monkey peripheral mononuclear cells: induction of CC chemokine receptor 5 expression for virus entry. J Infect Dis 185:1826–1829PubMedGoogle Scholar
  146. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42:71S–81SPubMedGoogle Scholar
  147. Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, Gold J, Penny R (1988) The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med 18:8–15PubMedGoogle Scholar
  148. Tseng RJ, Padgett DA, Dhabhar FS, Engler H, Sheridan JF (2005) Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids. Brain Behav Immun 19:153–164PubMedGoogle Scholar
  149. Urbina A, Jones K (2004) Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 38:890–894PubMedGoogle Scholar
  150. Vallejo R, de Leon-Casasola O, Benyamin R (2004) Opioid therapy and immunosuppression: a review. Am J Ther 11:354–365PubMedGoogle Scholar
  151. Vlahov D, Anthony JC, Celentano D, Solomon L, Chowdhury N (1991) Trends in HIV-1 risk reduction among initiates into intravenous drug use 1982–1987. Am J Drug Alcohol Abuse 17:39–48PubMedGoogle Scholar
  152. Vongsheree S, Sri-Ngam P, Ruchusatsawat N, Thaisri H, Puangtabtim W, Phutiprawan T, Sawanpanyalert P (2001) High HIV-I prevalence among metamphetamine users in central Thailand, 1999–2000. J Med Assoc Thai 84:1263–1267PubMedGoogle Scholar
  153. Wada K, Greberman SB, Konuma K, Hirai S (1999) HIV and HCV infection among drug users in Japan. Addiction 94:1063–1069PubMedGoogle Scholar
  154. Wallace JM, Lim R, Browdy BL, Hopewell PC, Glassroth J, Rosen MJ, Reichman LB, Kvale PA (1998) Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 114:131–137PubMedGoogle Scholar
  155. Wang X, Tan N, Douglas SD, Zhang T, Wang YJ, Ho WZ (2005) Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells. J Leukoc Biol 78: 772–776PubMedGoogle Scholar
  156. Watson RR (1993) Resistance to intestinal parasites during murine AIDS: role of alcohol and nutrition in immune dysfunction. Parasitology 107 Suppl:569–574Google Scholar
  157. Watson ES, Murphy JC, ElSohly HN, ElSohly MA, Turner CE (1983) Effects of the administration of coca alkaloids on the primary immune responses of mice: interaction with delta 9-tetrahydrocannabinol and ethanol. Toxicol Appl Pharmacol 71:1–13PubMedGoogle Scholar
  158. Welters I (2003) Opioids and immunosuppression. Clinical relevance? Anaesthesist 52:442–452PubMedGoogle Scholar
  159. Wetzel MA, Steele AD, Eisenstein TK, Adler MW, Henderson EE, Rogers TJ (2000) Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-l0 expression in human peripheral blood mononuclear cells. J Immunol 165:6519–6524PubMedGoogle Scholar
  160. Whitfield RM, Bechtel LM, Starich GH (1997) The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res 21:122–127PubMedGoogle Scholar
  161. Wohl AR, Johnson DF, Lu S, Jordan W, Beall G, Currier J, Simon PA (2002) HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr 31:354–360PubMedGoogle Scholar
  162. Wolfe SA, Culpe SG, De Souza EB (1989) Sigma-receptors in endocrine organs: identification, characterization and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 124:1160–1172PubMedCrossRefGoogle Scholar
  163. Wolfe H, Vraizan KM, Gorter RG, Keffelew AS, Moss AR (1992) Crack use and human immunodeficiency virus infection among San Francisco intravenous drug users. Sex Transm Dis 19:111–114PubMedCrossRefGoogle Scholar
  164. Woolverton WL (1992) Determinants of cocaine self-administration by laboratory animals. Ciba Found Symp 166:149–161PubMedGoogle Scholar
  165. Xu W, Bai F, Tummalapalli CM, Miller DD, Middaugh L, Boggan WO (1997) The interactive effects of cocaine/gender on immune function in mice. An observation of in vivo acute cocaine exposure. Int J Immunopharmacol 19:333–340PubMedGoogle Scholar
  166. Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83:500–508PubMedGoogle Scholar
  167. Yu Q, Montes S, Larson DF, Watson RR (2002a) Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci 71:953–965PubMedGoogle Scholar
  168. Yu Q, Zhang D, Walston M, Zhang J, Liu Y, Watson RR (2002b) Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol 2:951–962PubMedGoogle Scholar
  169. Zhang P, Bagby GJ, Happel KI, Sumner WR, Nelson S (2002) Pulmonary host defenses and alcohol. Front Biosci 7:d1314–d1330PubMedGoogle Scholar
  170. Zhu LX, Sharma 5, Gardner B, Escuadro B, Atianzar K, Tashkin DP, Dubinett SM (2003) IL-1 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol 170:3585–3591PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of Microbiology and ImmunologyVirginia Commonwealth University, School of MedicineRichmondUSA

Personalised recommendations